CTI Plans To Spin Off Systems Medicine As Pharmacogenomics Company Apana
This article was originally published in The Pink Sheet Daily
New firm’s management team is looking for pharma partners to validate its expertise, attract venture funding while parent CTI struggles to stay in business.
You may also be interested in...
Buyer Spectrum downplays supplemental BLA delay in front-line non-Hodgkins lymphoma.
Company is on track to achieve goal of filing seven to 10 new products from the beginning of 2008 through end of 2010, CEO Weldon says.
Johnson & Johnson’s Yondelis is in competition with Systems Medicine’s brostallicin to become first minor groove binding agent on the market.